A new pilot project under the European drug agency EMA seeks to establish a dialogue with companies concerning the prospect of early approval of drugs for a limited number of patients, Steffen Thirstrup informs.
A new survey ranks 50 Danish CEOs on parameters such as popularity and credibility. For the first year ever, Novo Nordisk CEO Lars Rebien has been dethroned and forced to give up the top slot to Lars Rasmussen from Coloplast. Read on to see how all of the Danish life science executives rank.
It eats away at patent protection, when drug companies are forced to lower prices on their medicine in order to win reimbursement. It will harm patients in the long run, says Sanofi’s chief of the Nordic and Baltic regions.
If the FDA approval of main asset Beleodaq comes together, Topotarget will need a number of new employees over the coming years. Moreover, the company’s new strategy shows that the tactical M&A game has begun.
An American NBA legend known as The Human Highlight Film due to his awe-inspiring slam dunks will be the new spokesperson for Novo Nordisk’s Victoza in the US after disgraced celebrity chef Paula Dean.
The listed, Danish gene analysis company Exiqon has great difficulty recruiting new employees in Denmark. The high wage level at, for example, Novo Nordisk is part of the explanation, CEO Lars Kongsbak reveals.
The acquisition of new pump technology will help drive growth in Danish medtech outfit Ambu and bring annual revenue of USD 370 million. The company has already closed deals that could add millions in sales and the ultimate market potential is believed to be in the multi-millions.
Head of diabetes research Peter Kurtzhals says Novo Nordisk’s Danish R&D-unit is set to grow by more than 50% over the next 8 years and he expects to employ more foreign scientists, as there are simply too few Danish candidates.
ALK approaches the market with a treatment for the most commercially important allergi. The company’s pill against house dust mite allergy could be launched in EU and Japan in 2015, with the US market following in 2016, and the first step toward the massive Chinese market has just been taken, says ALK’s top chief.
All beginnings are difficult and the sales numbers for Zealand Pharma’s diabetes drug Lyxumia for 2013 reflect that notion. But the company has launched a drug that is bound to become a blockbuster and the company is now betting on more than a hope or a dream, CEO David Solomon points out.
Rival Biogen Idec is set to hit the market first with its long-acting hemophilia A drug, but Novo Nordisk and Bayer have stronger market positions, which could be hugely important on a conservative market, says a sector analyst.
Bavarian Nordic has become better at producing more small pox vaccines for less money, which has created the foundation for a budding profitable business. While the US government’s orders of a small pox vaccine drive sales, EU only accounts for small, but promising, order quantities.
One of the world’s biggest pharma players has shelved its sternly criticized sales methods to avoid having its integrity questioned due to unethical financial incentives, which could ultimately prove harmful to patients. But Novo Nordisk, Lundbeck and Leo Pharma are standing up for those very same methods.
Candidate drug Brexpiprazole is the diamond in the rough in Lundbeck’s pipeline, say analysts. The blockbuster candidate, which is used to treat mental disorders, is expected to hit the market as early as 2015.
It is one thing that the potential in Genmab’s deal with Janssen has been doubled, but another crucial aspect of the deal is that it has a “huge impact” on the company’s future prospects, says Jan van de Winkel.